AR062 / Y-Biologics - LARVOL DELTA

Y Biologics announces research results on anti-CD39 antibody 'AR062' at AACR [Google translation] (HIT News) - "Y Biologics...officially announced the research results of anti-CD39 antibody 'AR062 (development code name)' submitted to the 2024 American Association for Cancer Research Annual Meeting...Y Biologics plans to present research results on the characteristics and efficacy of AR062 at this event. AR062 is an anti-CD39 monoclonal antibody....According to the research results, AR062 effectively inhibited CD39 from converting ATP to adenosine, while allowing the accumulation of ATP, which helps activate immune cells. This means that the tumor microenvironment (TME), which suppresses immune activity, is changed into an environment in which immune cells can be activated, and the treatment effect of immunotherapy anticancer drugs can be expected to improve through combined administration."

Preclinical • Oncology • Solid Tumor